Share This Article:

Evaluation of the Aurora Kinase Inhibitor, ZM447439, in Canine Malignant Lymphoid Cells in Vitro

Abstract Full-Text HTML XML Download Download as PDF (Size:839KB) PP. 29-38
DOI: 10.4236/ojvm.2013.31006    3,849 Downloads   6,203 Views   Citations

ABSTRACT

Aurora kinases play an important role in the cell cycle. These enzymes help establish mitotic spindles by directing centrosome duplication and separation and by regulating the spindle assembly checkpoint thereby helping control cytokinesis. An over-expression of aurora kinases has been reported in a variety of human tumors. In this study, we identified the expression of aurora-A and aurora-B kinases in canine malignant lymphoid cells. We also evaluated the effects of the aurora kinase inhibitor (ZM447439), and found that this inhibitor decreases cell viability, increases DNA content change, and leads to apoptosis in canine B- and T-cell lymphoid cell lines. The lymphotoxicity induced by ZM447439 in these canine lymphoid cell lines suggests that further in vivo evaluation of aurora kinase inhibitors as a potential treatment for canine malignant lymphoid tumors is warranted.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

K. Shiomitsu, X. Xia, K. Waite, I. Sehgal and S. Li, "Evaluation of the Aurora Kinase Inhibitor, ZM447439, in Canine Malignant Lymphoid Cells in Vitro," Open Journal of Veterinary Medicine, Vol. 3 No. 1, 2013, pp. 29-38. doi: 10.4236/ojvm.2013.31006.

References

[1] K. E. Flood-Knapik, A. C. Durham, T. P. Gregor, M. D. Sánchez, M. E. Durney and K. U. Sorenmo, “Clinical, Histopathological and Immunohistochemical Characterization of Canine Indolent Lymphoma,” Veterinary Comparative Oncology, 2012, in press.
[2] L. D. Garrett, D. H. Thamm, R. Chun, R. Dudley and D. M. Vail, “Evaluation of 6-Month Chemotherapy Protocol with No Maintenance Therapy for Dogs with Lymphoma,” Journal of Veterinary Internal Medicine, Vol. 16, No. 6, 2002, pp. 704-709.
[3] R. Chun, L. D. Garrentt and D. M. Vail, “Cancer Chemotherapy,” In: S. J. Withrow and D. M. Vail, Eds., Withrow and MacEwen’s Small Animal Clinical Oncology, 4th Edition, Saunders Elsevier, St. Louis, 2007, pp. 163-191.
[4] E. M. Brodsky, G. N. Maudlin, J. L. Lachowicz and G. S. Post, “Asparaginase and MOPP Treatment of Dogs with Lymphoma,” Journal of Veterinary Internal Medicine, Vol. 23, No. 3, 2009, pp. 578-584. doi:10.1111/j.1939-1676.2009.0289.x
[5] K. A. Schafer, “The Cell Cycle: A Review,” Veterinary Pathology, Vol. 35, No. 6, 1998, pp. 461-478. doi:10.1177/030098589803500601
[6] G. Mountzios, E. Terpos and M. A. Dimopoulos, “Aurora Kinases as Targets for Cancer Therapy,” Cancer Treatment Review, Vol. 34, No. 2, 2008, pp. 175-182. doi:10.1016/j.ctrv.2007.09.005
[7] S. S. Farag, “The Potential Role of Aurora Kinase Inhibitors in Haematological Malignancies,” British Journal of Haematology, Vol. 155, No. 5, 2011, pp. 561-579. doi:10.1111/j.1365-2141.2011.08898.x
[8] S. Sen, H. Zhou, R. D. Zhang, D. S. Yoon, F. Vakar- Lopez, S. Ito, F. Jiang, D. Johnston, H. B. Grossman, A. C. Ruifrok, R. L. Katz, W. Brinkley and B. Czerniak, “Amplification/Overexpression of a Mitotic Kinase Gene in Human Bladder Cancer,” Journal of the National Cancer Institute, Vol. 94, No. 17, 2002, pp. 1320-1329. doi:10.1093/jnci/94.17.1320
[9] T. Takahashi, M. Futamura, N. Yoshimi, J. Sano, M. Katada, Y. Takagi, M. Kimura, T. Yoshioka, Y. Okano, and S. Saji, “Centrosomal Kinase, HsAIRK1 and HsAIRK3, Are Overexpressed in Primary Colorectal Cancers,” Japanese Journal of Cancer Research, Vol. 91, No. 10, 2000, pp. 1007-1014. doi:10.1111/j.1349-7006.2000.tb00878.x
[10] T. Tong, Y. Zhong, J. Kong, L. Dong, Y. Song, M. Fu, Z. Liu, M. Wang, L. Guo, S. Lu, M. Wu and Q. Zhan, “Overexpression of Aurora-A Contributes to Malignant Development of Human Esophageal Squamous Cell Carcinoma,” Clinical Cancer Research, Vol. 10, No. 21, 2004, pp. 7304-7310. doi:10.1158/1078-0432.CCR-04-0806
[11] A. Klein, W. Reichardt, V. Jung, K. D. Zang, E. Meese and S. Urbschat, “Overexpression and Amplification of STK15 in Human Gliomas,” International Journal of Oncology, Vol. 25, No. 6, 2004, pp. 1789-1794.
[12] S. Rojanala, H. Han, R. M. Muńoz, W. Browne, R. Nagle, D. D. Von Hoff and D. J. Bearss, “The Mitotic Serine Threonine Kinase, Aurora-2, Is a Potential Target for Drug Development in Human Pancreatic Cancer,” Molecular Cancer Therapeutics, Vol. 3, No. 4, 2004, pp. 451- 457.
[13] H. M. Buschhorn, R. R. Klein, S. M. Chambers, M. C. Hardy, S. Green, D. Bearss and R. B. Nagle, “Aurora-A Overexpression in High-Grade PIN Lesions and Prostate Cancer,” Prostate, Vol. 64, No. 4, 2005, pp. 341-346. doi:10.1002/pros.20247
[14] M. Carmena and W. C. Earnshaw, “The Cellular Geography of Aurora Kinases,” Nature Reviews. Molecular Cell Biology, Vol. 4, No. 11, 2003, pp. 842-845. doi:10.1038/nrm1245
[15] M. T. Parra, A. Viera, R. Gómez, J. Page, M. Camena, W. C. Earnshaw, J. S. Rufas and J. A. Suja, “Dynamic Relocalization of the Chromosomal Passenger Complex Proteins Inner Centromere Protein (INCENP) and Aurora-B Kinase during Male Mouse Meiosis,” Journal of Cell Science, Vol. 116, No. 6, 2003, pp. 961-974. doi:10.1242/jcs.00330
[16] J. J. Kitzen, M. J. de Jonge and J. Verweij, “Aurora Kinase Inhibitors,” Critical Reviews in Oncology/Hematology, Vol. 73, No. 2, 2010, pp. 99-110. doi:10.1016/j.critrevonc.2009.03.009
[17] C. Ditchfield, V. L. Johnson, A. Tighe, R. Ellston, C. Haworth, T. Johnson, A. Mortlock, N. Keen and S. S. Taylor, “Aurora B Couples Chromosome Alignment with Anaphase by Targeting BubR1, Mad2, and Cenp-E to Kinetochores, ”Journal Cell Biology, Vol. 161, No. 2, 2003, pp. 267-280. doi:10.1083/jcb.200208091
[18] B. B. Gadea and J. V. Ruderman, “Aurora Kinase Inhibitor ZM447439 Blocks Chromosome-induced Spindle Assembly, the Completion of Chromosome Condensation, and the Establishment of the Spindle Integrity Checkpoint in Xenopus Egg Extracts,” Molecular Biology of the Cell, Vol. 16, No. 3, 2005, pp. 1305-1318. doi:10.1091/mbc.E04-10-0891
[19] N. Steeghs, F. A. Eskens, H. Gelderblom, J. Verweij, J. W. Nortier, J. Ouwerkerk, C. van Noort, M. Mariani, R. Spinelli, P. Carpinelli, B. Laffranchi and M. J. de Jonge, “Phase I Pharmacokinetic and Pharmacodynamic Study of the Aurora Kinase Inhibitor Danusertib in Patients with Advanced or Metastatic Solid Tumors,” Journal of Clinical Oncology, Vol. 27, No. 30, 2009, pp. 5094-5101. doi:10.1200/JCO.2008.21.6655
[20] T. Macarulla, A. Cervantes, E. Elez, E. Rodriguez-Braun, J. Baselga, S. Roselló, G. Sala, I. Blasco, H. Danaee, Y. Lee, J. Ecsedy, V. Shinde, A. Chakravarty, D. Bowman, H. Liu, O. Eton, H. Fingert and J. Tabernero, “Phase I Study of the Selective Aurora A Kinase Inhibitor MLN- 8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics,” Molecular Cancer Therapeutics, Vol. 9, No. 10, 2010, pp. 2844- 2852. doi:10.1158/1535-7163.MCT-10-0299
[21] A. M. Traynor, M. Hewitt, G. Liu, K. T. Flaherty, J. Clark, S. J. Freedman, B. B. Scott, A. M. Leighton, P. A. Watson, B. Zhao, P. J. O’Dwyer and G. Wilding, “Phase I Dose Escalation Study of MK-0457, a Novel Aurora Kinase Inhibitor, in Adult Patients with Advanced Solid Tumors,” Cancer Chemotherapy and Pharmacology, Vol. 67, No. 2, 2011, pp. 305-314. doi:10.1007/s00280-010-1318-9
[22] J. R. Diamond, B. R. Bastos, R. J. Hansen, D. L. Gustafson, S. G. Eckhardt, E. L. Kwak, S. S. Pandya, G. C. Fletcher, T. M. Pitts, G. N. Kulikowski, M. Morrow, J. Arnott, M. R. Bray, C. Sidor, W. Messersmith and G. I. Shapiro, “Phase I Safety, Pharmacokinetic, and Pharmacodynamics Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors,” Clinical Cancer Research, Vol. 17, No. 4, 2011, pp. 849-860. doi:10.1158/1078-0432.CCR-10-2144
[23] A. Chakravarty, V. Shinde, J. Tabernero, A. Ceravantes, R. B. Cohen, E. C. Dees, H. Burris, J. R. Infante, T. Macarulla, E. Elez, J. Andreu, E. Rodriguez-Braun, S. Rosello, M. von Mehren, N. J. Meropol, C. J. Langer, B. ONeil, D. Bowman, M. Zhang, H. Danaee, L. Faron- Yowe, G. Gray, H. Liu, J. Pappas, L. Silverman, C. Simpson, B. Stringer, S. Tirrell, O. P. Veiby, K. Venkatakrishnan, K. Galvin, M. Manfredi and J. A. Ecsedy, “Phase I Assessment of New Mechanism-Based Pharmacodynamics Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora a Kinase,” Cancer Research, Vol. 71, No. 3, 2011, pp. 675-685. doi:10.1158/0008-5472.CAN-10-1030
[24] M. Nakaichi, Y. Taura, M. Kanki, K. Mamba, Y. Momoi, H. Tsujimoto and A. Nakama, “Establishment and Characterization of a New Canine B-Cell Leukemia Cell Line,” Journal of Veterinary Medical Science, Vol. 58, No. 5, 1996, pp. 469-471. doi:10.1292/jvms.58.469
[25] H. Hiraoka, K. Minami, N. Kaneko, T. Shimokawa Miyama, Y. Okamura, T. Mizuno and M. Okuda, “Aberrations of the FHIT Gene and Fhit Protein in Canine Lymphoma Cell Lines,” Journal of Veterinary Medical Science, Vol. 71, No. 6, 2009, pp. 769-777. doi:10.1292/jvms.71.769
[26] S. M. Wiseman, H. Masoudi, P. Niblock, D. Turbin, A. Rajput, J. Hay, S. Bugis, D. Filipenko, D. Huntsman and B. Gilks, “Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment,” Annals of Surgical Oncology, Vol. 14, No. 2, 2007, pp. 719-729. doi:10.1245/s10434-006-9178-6
[27] Z. Guan, X. R. Wang, X. F. Zhu, X. F. Huang, J. Xu, L. H. Wang, X. B. Wan, Z. J. Long, J. N. Liu, G. K. Feng, W. Huang, Y. X. Zeng, F. J. Chen and Q. Liu, “Aurora-A, a Negative Prognostic Marker, Increases Migration and Decreases Radiosensitivity in Cancer Cells,” Cancer Research, Vol. 67, No. 21, 2007, pp. 10436-10444. doi:10.1158/0008-5472.CAN-07-1379
[28] R. Reiter, P. Gais, U. Jütting, M. K. Steuer-Vogt, A. Pickhard, K. Bink, S. Rauser, S. Lassmann, H. H?fler, M. Werner and A. Walch, “Aurora Kinase A Messenger RNA Overexpression Is Correlated with Tumor Progression and Shortened Survival in Head and Neck Squamous Cell Carcinoma,” Clinical Cancer Research, Vol. 12, No. 17, 2006, pp. 5136-5141. doi:10.1158/1078-0432.CCR-05-1650
[29] F. Yang, X. Guo, D. G. Rosen and J. Liu, “AURKA and BRCA2 Expression Highly Correlate with Prognosis of Endometrioid Ovarian Carcinoma,” Modern Pathology, Vol. 24, No. 6, 2011, pp. 836-845. doi:10.1038/modpathol.2011.44
[30] N. Mori, C. Ishikawa, M. Senba, M. Kimura and Y. Okano, “Effects of AZD1152, a Selective Aurora B Kinase Inhibitor, on Burkitt’s and Hodgkin’s Lymphomas,” Biochemical Pharmacology, Vol. 81, No. 9, 2011, pp. 1106- 1115. doi:10.1016/j.bcp.2011.02.010
[31] T. Ikezoe, J. Yang, C. Nishioka, T. Tasaka, A. Taniguchi, Y. Kuwayama, N. Komatsu, K. Bandobashi, K. Togitani, H. P. Koeffler and H. Taguchi, “A Novel Treatment Strategy Targeting Aurora Kinases in Acute Myelogenous Leukemia,” Molecular Cancer Therapeutics, Vol. 6, No. 6, 2007, pp. 1851-1857. doi:10.1158/1535-7163.MCT-07-0067
[32] I. Georgieva, D. Koychev, Y. Wang, J. Holstein, W. Hopfenmüller, M. Zeitz and P. Grabowski, “ZM447439, a Novel Promising Aurora Kinase Inhibitor, Provokes Antiproliferative and Proapoptotic Effects Alone and in Combination with Bio- and Chemotherapeutic Agents in Gastroenteropacreatic Neuroendocrine Tumor Cell Lines,” Neuroendocrinology, Vol. 91, No. 2, 2010, pp. 121-130. doi:10.1159/000258705
[33] L. M. Beaver, G. Strotttner and M. K. Klein, “Response Rate after Administration of a Single Dose of Doxorubicin in Dogs with B-Cell or T-Cell Lymphoma: 41 Cases (2006-2008),” Journal of American Veterinary Medical Association, Vol. 237, No. 9, 2010, pp. 1052-1055. doi:10.2460/javma.237.9.1052
[34] R. W. Wilkinson, R. Odedra, S. P. Heaton, S. R. Wedge, N. J. Keen, C. Crafter, J. R. Foster, M. C. Brady, A. Bigley, E. Brown, K. F. Byth, N. C. Barrass, K. E. Mundt, K. M. Foote, N. M. Heron, F. H. Jung, A. A. Mortlock, F. T. Boyle and S. Green, “AZD1152, a Selective Inhibitor of Aurora B Kinase, Inhibits Human Tumor Xenograft Growth by Inducing Apoptosis,” Clinical Cancer Research, Vol. 13, No. 12, 2007, pp. 3682-3688. doi:10.1158/1078-0432.CCR-06-2979
[35] R. P. Evans, C. Naber, T. Steffler, T. Checkland, C. A. Maxwell, J. J. Keats, A. R. Belch, L. M. Pilarski, R. Lai and T. Reiman, “The Selective Aurora B Kinase Inhibitor AZD1152 Is a Potential New Treatment for Multiple Myeloma,” British Journal of Haematology, Vol. 140, No. 3, pp. 295-302. doi:10.1111/j.1365-2141.2007.06913.x

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.